PDF herunterladen
Semin Reprod Med 2015; 33(02): 153-158
DOI: 10.1055/s-0035-1546303
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Difficult In Vitro Fertilization Patient: An Individualized Approach

David Reichman
1   The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medical College, New York, New York
,
Zev Rosenwaks
1   The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medical College, New York, New York
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
03. März 2015 (online)

   Lizenzen und Reprints

Abstract

In general, standardized in vitro fertilization (IVF) protocols and practice regimens can be applied with success for most patients. Such approaches, however, may not be effective for some women who do not “fit the mold” and for whom highly individualized treatments are more suitable. In this article, we outline our personal experience and treatment approaches for these challenging patients.

Keywords

in vitro fertilization - assisted reproductive technology - difficult patient - challenging
 

  • References

  • 1 Fatemi HM, Popovic-Todorovic B, Humaidan P , et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril 2014; 101 (4) 1008-1011
    CrossrefPubMedSuche in Google Scholar
  • 2 Yovich J, Stanger J, Hinchliffe P. Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS. Reprod Biomed Online 2012; 24 (3) 281-292
    CrossrefPubMedSuche in Google Scholar
  • 3 Tsakos E, Tolikas A, Daniilidis A, Asimakopoulos B. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET. Arch Gynecol Obstet 2014; 290 (6) 1249-1253
    CrossrefPubMedSuche in Google Scholar
  • 4 La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014; 20 (1) 124-140
    Suche in Google Scholar
  • 5 Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T, Tapanainen JS. Antimüllerian hormone levels decrease in women using combined contraception independently of administration route. Fertil Steril 2013; 99 (5) 1305-1310
    CrossrefPubMedSuche in Google Scholar
  • 6 Johnson LN, Sammel MD, Dillon KE, Lechtenberg L, Schanne A, Gracia CR. Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception. Fertil Steril 2014; 102 (3) 774-781.e3
    CrossrefPubMedSuche in Google Scholar
  • 7 Steward RG, Lan L, Shah AA , et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril 2014; 101 (4) 967-973
    CrossrefPubMedSuche in Google Scholar
  • 8 Imudia AN, Awonuga AO, Doyle JO , et al. Peak serum estradiol level during controlled ovarian hyperstimulation is associated with increased risk of small for gestational age and preeclampsia in singleton pregnancies after in vitro fertilization. Fertil Steril 2012; 97 (6) 1374-1379
    CrossrefPubMedSuche in Google Scholar
  • 9 Humaidan P, Kol S, Papanikolaou EG ; Copenhagen GnRH Agonist Triggering Workshop Group. GnRH agonist for triggering of final oocyte maturation: time for a change of practice?. Hum Reprod Update 2011; 17 (4) 510-524
    CrossrefPubMedSuche in Google Scholar
  • 10 Ludwig M, Felberbaum RE, Devroey P , et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet 2000; 264 (1) 29-32
    CrossrefPubMedSuche in Google Scholar
  • 11 Felberbaum RE, Albano C, Ludwig M , et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod 2000; 15 (5) 1015-1020
    CrossrefPubMedSuche in Google Scholar
  • 12 Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod 2000; 15 (9) 1965-1968
    CrossrefPubMedSuche in Google Scholar
  • 13 Gibreel A, Maheshwari A, Bhattacharya S. Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database Syst Rev 2012; 11: CD008528
    PubMedSuche in Google Scholar
  • 14 Shalom-Paz E, Marzal A, Wiser A, Hyman J, Tulandi T. Does optimal follicular size in IUI cycles vary between clomiphene citrate and gonadotrophins treatments?. Gynecol Endocrinol 2014; 30 (2) 107-110
    CrossrefPubMedSuche in Google Scholar
  • 15 Farhi J, Orvieto R, Gavish O, Homburg R. The association between follicular size on human chorionic gonadotropin day and pregnancy rate in clomiphene citrate treated polycystic ovary syndrome patients. Gynecol Endocrinol 2010; 26 (7) 546-548
    CrossrefPubMedSuche in Google Scholar
  • 16 Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Hum Reprod 1997; 12 (11) 2359-2365
    CrossrefPubMedSuche in Google Scholar
  • 17 Kashyap S, Parker K, Cedars MI, Rosenwaks Z. Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose. Semin Reprod Med 2010; 28 (6) 475-485
    Thieme ConnectPubMedSuche in Google Scholar
  • 18 Reichman DE, Goldschlag D, Rosenwaks Z. Value of antimüllerian hormone as a prognostic indicator of in vitro fertilization outcome. Fertil Steril 2014; 101 (4) 1012-8.e1
    CrossrefPubMedSuche in Google Scholar
  • 19 Reichman DE, Gunnala V, Meyer L , et al. In vitro fertilization versus conversion to intrauterine insemination in the setting of three or fewer follicles: how should patients proceed when follicular response falls short of expectation?. Fertil Steril 2013; 100 (1) 94-99
    CrossrefPubMedSuche in Google Scholar
  • 20 Shastri SM, Barbieri E, Kligman I, Schoyer KD, Davis OK, Rosenwaks Z. Stimulation of the young poor responder: comparison of the luteal estradiol/gonadotropin-releasing hormone antagonist priming protocol versus oral contraceptive microdose leuprolide. Fertil Steril 2011; 95 (2) 592-595
    CrossrefPubMedSuche in Google Scholar
  • 21 Fanchin R, Cunha-Filho JS, Schonäuer LM, Kadoch IJ, Cohen-Bacri P, Frydman R. Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens. Fertil Steril 2003; 79 (2) 316-321
    CrossrefPubMedSuche in Google Scholar
  • 22 Fanchin R, Castelo Branco A, Kadoch IJ, Hosny G, Bagirova M, Frydman R. Premenstrual administration of gonadotropin-releasing hormone antagonist coordinates early antral follicle sizes and sets up the basis for an innovative concept of controlled ovarian hyperstimulation. Fertil Steril 2004; 81 (6) 1554-1559
    CrossrefPubMedSuche in Google Scholar
  • 23 Dragisic KG, Davis OK, Fasouliotis SJ, Rosenwaks Z. Use of a luteal estradiol patch and a gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation for in vitro fertilization in poor responders. Fertil Steril 2005; 84 (4) 1023-1026
    CrossrefPubMedSuche in Google Scholar
  • 24 Frattarelli JL, Hill MJ, McWilliams GD, Miller KA, Bergh PA, Scott Jr RT. A luteal estradiol protocol for expected poor-responders improves embryo number and quality. Fertil Steril 2008; 89 (5) 1118-1122
    CrossrefPubMedSuche in Google Scholar
  • 25 Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum Reprod 2005; 20 (3) 611-615
    CrossrefPubMedSuche in Google Scholar
  • 26 van Hooff MH, Alberda AT, Huisman GJ, Zeilmaker GH, Leerentveld RA. Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod 1993; 8 (3) 369-373
    PubMedSuche in Google Scholar
  • 27 Baart EB, Martini E, Eijkemans MJ , et al. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod 2007; 22 (4) 980-988
    CrossrefPubMedSuche in Google Scholar
  • 28 Benadiva CA, Davis O, Kligman I, Liu HC, Rosenwaks Z. Clomiphene citrate and hMG: an alternative stimulation protocol for selected failed in vitro fertilization patients. J Assist Reprod Genet 1995; 12 (1) 8-12
    CrossrefPubMedSuche in Google Scholar
  • 29 Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 2004; 82 (1) 102-107
    PubMedSuche in Google Scholar
  • 30 Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzis BC, Tournaye H, Devroey P. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial. Fertil Steril 2011; 96 (5) 1112-1115
    CrossrefPubMedSuche in Google Scholar
  • 31 Kasius A, Smit JG, Torrance HL , et al. Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis. Hum Reprod Update 2014; 20 (4) 530-541
    CrossrefPubMedSuche in Google Scholar
  • 32 Zhang X, Chen CH, Confino E, Barnes R, Milad M, Kazer RR. Increased endometrial thickness is associated with improved treatment outcome for selected patients undergoing in vitro fertilization-embryo transfer. Fertil Steril 2005; 83 (2) 336-340
    CrossrefPubMedSuche in Google Scholar
  • 33 Dain L, Bider D, Levron J, Zinchenko V, Westler S, Dirnfeld M. Thin endometrium in donor oocyte recipients: enigma or obstacle for implantation?. Fertil Steril 2013; 100 (5) 1289-1295
    CrossrefPubMedSuche in Google Scholar
  • 34 Gleicher N, Kim A, Michaeli T , et al. A pilot cohort study of granulocyte colony-stimulating factor in the treatment of unresponsive thin endometrium resistant to standard therapies. Hum Reprod 2013; 28 (1) 172-177
    CrossrefPubMedSuche in Google Scholar
  • 35 Hong KH, Forman EJ, Werner MD , et al. Endometrial infusion of human chorionic gonadotropin at the time of blastocyst embryo transfer does not impact clinical outcomes: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2014; 102 (6) 1591-1595.e2
    CrossrefPubMedSuche in Google Scholar
  • 36 Check JH, Graziano V, Lee G, Nazari A, Choe JK, Dietterich C. Neither sildenafil nor vaginal estradiol improves endometrial thickness in women with thin endometria after taking oral estradiol in graduating dosages. Clin Exp Obstet Gynecol 2004; 31 (2) 99-102
    PubMedSuche in Google Scholar
  • 37 Sher G, Fisch JD. Effect of vaginal sildenafil on the outcome of in vitro fertilization (IVF) after multiple IVF failures attributed to poor endometrial development. Fertil Steril 2002; 78 (5) 1073-1076
    CrossrefPubMedSuche in Google Scholar
  • 38 Sher G, Fisch JD. Vaginal sildenafil (Viagra): a preliminary report of a novel method to improve uterine artery blood flow and endometrial development in patients undergoing IVF. Hum Reprod 2000; 15 (4) 806-809
    CrossrefPubMedSuche in Google Scholar